Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia

View All

Jul 9, 2020 • 8:19 AM EDT

Rigel Announces Availability of TAVLESSE® (Fostamatinib Disodium Hexahydrate) in Europe

Jun 17, 2020 • 7:30 AM EDT

Rigel to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference

Jun 11, 2020 • 7:30 AM EDT

Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress

May 2020

View Presentation

BMO 2020 Prescriptions for Success Healthcare Virtual Conference

View Event View All

Q1 2020

Quarter Ended Mar 31, 2020

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080